Chronic Obstructive Pulmonary Disease Market

Market Overview: 

The 7 major chronic obstructive pulmonary disease markets reached a value of US$ 13,464.0 Million in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 18,551.6 Million by 2034, exhibiting a growth rate (CAGR) of 2.96% during 2024-2034.

The chronic obstructive pulmonary disease market has been comprehensively analyzed in IMARC's new report titled "Chronic Obstructive Pulmonary Disease Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Chronic obstructive pulmonary disease (COPD) refers to a chronic respiratory disorder characterized by persistent airflow limitation due to the inflammation of airways and destruction of lung tissue. The most common symptoms of the ailment include shortness of breath, wheezing, chest tightness, chronic cough, excess mucus production, etc. These indications can make it difficult for individuals with COPD to breathe, leading to fatigue, difficulty with physical activity, and reduced quality of life. In advanced stages, COPD can also cause weight loss, depression, and other systemic effects. The diagnosis of the ailment typically involves a combination of medical history, physical examination, lung function tests, and imaging studies. The medical history may include questions about the symptoms, smoking, exposure to environmental irritants, and family history of lung disease. Numerous imaging procedures, such as chest X-rays and CT scans, help identify structural abnormalities in the lungs. In some cases, the healthcare professional may also perform a blood test to evaluate other potential causes of the symptoms.

The increasing incidences of prolonged exposure to lung irritants like tobacco smoke and air pollutants, which damage the lungs by causing inflammation as well as narrowing of the airways, are primarily driving the chronic obstructive pulmonary disease market. In addition to this, the rising prevalence of several associated risk factors, such as exposure to chemical fumes, genetic predisposition, certain respiratory infections, including pneumonia and bronchitis, etc., is also bolstering the market growth. Furthermore, the widespread adoption of numerous medications, such as bronchodilators, corticosteroids, phosphodiesterase-4 inhibitors, etc., to open the airways, reduce inflammation, and improve lung functioning is acting as another growth-inducing factor. Besides this, the escalating utilization of lung volume reduction surgery (LVRS) for treating selected patients with severe COPD who have significant emphysema is further creating a positive outlook for the market. The LVRS procedure involves removing portions of damaged lung tissue, which helps to increase the elasticity of remaining lung tissues and enhances breathing efficiency. Moreover, the emerging popularity of non-invasive ventilation for improving breathing and oxygenation without the need for invasive procedures like intubation or mechanical ventilation in patients with severe COPD exacerbations, is expected to drive the chronic obstructive pulmonary disease market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the chronic obstructive pulmonary disease market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for chronic obstructive pulmonary disease and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the chronic obstructive pulmonary disease market in any manner.

Recent Developments:

• In April 2024, Amgen released an update on the findings of the Phase 2a COURSE study for TEZSPIRE (tezepelumab-ekko) in chronic obstructive pulmonary disease. It was observed that tezepelumab numerically reduced the annualized rate of moderate or severe COPD exacerbations by 17%.
• In March 2024, ASLAN Pharmaceuticals Ltd. published fresh, positive translational data from a head-to-head study of eblasakimab vs. dupilumab in a human tissue model of chronic obstructive pulmonary disease, which supports eblasakimab's potential as a biologic-therapy for COPD.
• In February 2024, Regeneron Pharmaceuticals, Inc. and Sanofi announced that the United States FDA had accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent (dupilumab) in a sixth potential indication as an add-on maintenance treatment in certain adult patients with uncontrolled chronic obstructive pulmonary disease.
• In September 2023, Verona Pharma plc stated that the US Food and Drug Administration (FDA) has approved the Company's New Drug Application (NDA) seeking approval of ensifentrine for the maintenance treatment of patients with chronic obstructive pulmonary disease.

Key Highlights:

• Chronic obstructive pulmonary disease is a major cause of disability and the sixth greatest cause of death in the United States, according to the Centers for Disease Control and Prevention (CDC).
• Globally, the prevalence of chronic obstructive pulmonary disease among both males and females was estimated to be 10.6%.
• Tobacco smoking is responsible for nearly 70% of COPD cases in high-income nations.
• Chronic obstructive pulmonary disease is the seventh greatest cause of poor health globally (measured by disability-adjusted life years).
• Low- and middle-income countries account for about 90% of all COPD fatalities among people under the age of 70.

Drugs:

Incruse Ellipta is an anticholinergic that has been licensed in the United States for the long-term, once-daily maintenance therapy of airflow obstruction in patients with chronic obstructive pulmonary disease. Incruse contains 62.5 mcg of umeclidinium given via the Ellipta inhaler.

Ensifentrine is a first-in-class, selective dual inhibitor of the phosphodiesterase 3 and 4 enzymes that combines bronchodilator and anti-inflammatory properties in a single molecule. In the Phase 3 ENHANCE-1 and ENHANCE-2 clinical trials, ensifentrine demonstrated significant and clinically meaningful improvements in lung function measurements while also lowering the rate of COPD exacerbations.

Tezspire (tezepelumab) is being developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of thymic stromal lymphopoietin (TSLP). This key epithelial cytokine sits at the top of multiple inflammatory cascades. It is critical in the initiation and persistence of allergic, eosinophilic, and other types of airway inflammation associated with severe asthma, including airway hyperresponsiveness.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the chronic obstructive pulmonary disease market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the chronic obstructive pulmonary disease market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current chronic obstructive pulmonary disease marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the chronic obstructive pulmonary disease market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the chronic obstructive pulmonary disease market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the chronic obstructive pulmonary disease market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (​2018-2034​) of chronic obstructive pulmonary disease across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of chronic obstructive pulmonary disease by age across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of chronic obstructive pulmonary disease by gender across the seven major markets?
• What is the number of prevalent cases (​2018-2034​) of chronic obstructive pulmonary disease by type across the seven major markets?
• How many patients are diagnosed (​2018-2034​) with chronic obstructive pulmonary disease across the seven major markets?
• What is the size of the chronic obstructive pulmonary disease patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of chronic obstructive pulmonary disease?
• What will be the growth rate of patients across the seven major markets?
   

Chronic Obstructive Pulmonary Disease: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for chronic obstructive pulmonary disease drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the chronic obstructive pulmonary disease market?
• What are the key regulatory events related to the chronic obstructive pulmonary disease market?
• What is the structure of clinical trial landscape by status related to the chronic obstructive pulmonary disease market?
• What is the structure of clinical trial landscape by phase related to the chronic obstructive pulmonary disease market?
• What is the structure of clinical trial landscape by route of administration related to the chronic obstructive pulmonary disease market?